Publications by authors named "Peter Compton"

Claim this Profile
T
The Crk adapter protein is essential for embryogenesis, where it regulates multiple actin-dependent morphogenic events.
Andrew J Spracklen, Emma M Thornton-Kolbe, Alison N Bonner, Alexandru Florea, Peter J Compton

Mol Biol Cell· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bevacizumab safety in patients with central nervous system metastases.
Benjamin Besse, Susan F Lasserre, Peter Compton, Jane Huang, Stella Augustus

Clin Cancer Res· January 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety of bevacizumab in patients with non-small-cell lung cancer and brain metastases.
Mark A Socinski, Corey J Langer, Jane E Huang, Margaret M Kolb, Peter Compton

J Clin Oncol· November 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety of efalizumab therapy in patients with moderate to severe psoriasis: an open-label extension of a phase IIIb trial.
Tiffani Hamilton, Alan Menter, Ivor Caro, Peter Compton, Jeffrey Sobell

Drug Saf· December 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A review of malignancies observed during efalizumab (Raptiva) clinical trials for plaque psoriasis.
Craig L Leonardi, Darryl Toth, Jennifer C Cather, Richard G B Langley, Winifred Werther, Peter Compton

Dermatology· January 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term continuous efalizumab therapy in patients with moderate to severe chronic plaque psoriasis: updated results from an ongoing trial.
Alice B Gottlieb, Tiffani Hamilton, Ivor Caro, Paul Kwon, Peter G Compton

J Am Acad Dermatol· April 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efalizumab retreatment in patients with moderate to severe chronic plaque psoriasis.
Kim A Papp, Bruce Miller, Kenneth B Gordon, Ivor Caro, Paul Kwon, Peter G Compton

J Am Acad Dermatol· April 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An overview of the pharmacokinetics and pharmacodynamics of efalizumab: a monoclonal antibody approved for use in psoriasis.
Amita Joshi, Robert Bauer, Peter Kuebler, Mark White, Cecelia Leddy, Peter Compton

J Clin Pharmacol· January 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety of efalizumab in patients with moderate to severe chronic plaque psoriasis: review of clinical data. part II.
Kim A Papp, Charles Camisa, Stephen P Stone, Ivor Caro, Xiaolin Wang, Peter Compton

J Cutan Med Surg· December 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical efficacy of efalizumab in patients with chronic plaque psoriasis: results from three randomized placebo-controlled Phase III trials: part I.
David M Pariser, Kenneth B Gordon, Kim A Papp, Craig L Leonardi, Paul Kwon, Peter G Compton

J Cutan Med Surg· December 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population pharmacokinetics of efalizumab (humanized monoclonal anti-CD11a antibody) following long-term subcutaneous weekly dosing in psoriasis subjects.
Yu-Nien Sun, Jian-Feng Lu, Amita Joshi, Peter Compton, Paul Kwon

J Clin Pharmacol· April 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase III trial.
Craig L Leonardi, Kim A Papp, Kenneth B Gordon, Alan Menter, Steven R Feldman, Peter G Compton

J Am Acad Dermatol· March 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis